Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: A meta-analysis

Neoplasia

Volumn 7, Issue 1, 2005, Pages 17-23

  Löhr, Matthias ^a   Klöppel, Günter ^b   Maisonneuve, Patrick ^c   Lowenfels, Albert B ^c,d   Lüttges, Jutta ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Chronic pancreatitis; K ras mutation; Meta analysis; Pancreatic ductal carcinoma; Pancreatic intraepithelial neoplasia

Indexed keywords

DNA;

ADENOCARCINOMA; ARTICLE; CHRONIC PANCREATITIS; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; GENE MUTATION; HUMAN; META ANALYSIS; NEOPLASM; ONCOGENE K RAS; PANCREAS DUCT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 13444274253     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04445     Document Type: Article

References (63)

1. Parkin DM, Pisari P, and Ferlay J (1999). Estimates of the world incidence of 25 major cancers in 1990. Int J Cancer 80, 827-841.
2. Urrutia R and DiMagno EP (1996). Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? (Editorial). Gastroenterology 110, 306-310.
3. Lowenfels AB and Maisonneuve P (2002). Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin North Am 16 (1), 1-16 (February).
4. Grützmann R, Foerder M, Alldinger I, Staub E, Brummendorf T, Ropcke S, Li X, Kristiansen G, Jesnowski R, Sipos B, Löhr M, Lüttges J, et al. (2003). Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 443 (4), 508-517.
5. Buchholz M, Boeck W, Fensterer H, Muller F, Wenger C, Michl P, Adler G, and Gress TM (2001). Use of DNA arrays/microarrays in pancreatic research. Pancreatology 1 (6), 581-586.
6. Hruban RH, van Mansfeld AD, Offershaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Camerons JL, and Bos JL (1993). k-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143, 545-554.
7. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, and Klöppel G (1992). Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 102, 230-236.
8. Moskaluk CA, Hruban RH, and Kern SE (1997). p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57 (11), 2140-2143 (June 1).
9. Lüttges J, Schlehe B, Menke MAOH, Vogel I, Henne-Bruns D, and Klöppel G (1999). The k-ras mutation pattern in pancreatic ductal adenocarcinoma is usually identical to that in associated normal, hyper-plastic and metaplastic duct epithelium. Cancer 85, 1703-1710.
10. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, Lüttges J, and Offerhaus GJ (2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25 (5), 579-586 (May).
11. Maire F, Micard S, Hammel P, Voitot H, Levy P, Cugnenc PH, Ruszniewski P, and Puig PL (2002). Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 87 (5), 551-554.
12. Lüttges J, Diederichs A, Menke MA, Vogel I, Kremer B, and Klöppel G (2000). Ductal lesions in patients with chronic pancreatitis show k-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity of p53. Cancer 88 (11), 2495-2504.
13. Lüttges J, Reinecke-Lüthge A, Möllmann B, Menke MAOH, Clemens A, Klimpfinger M, Sipos B, and Klöppel G (1999). Duct changes and k-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch 435 (1), 461-468.
14. Lindforss U, Papadogiannakis N, Zetterquist H, Lindberg G, and Olivecrona H (2003). Distribution of genetic variants in preneoplastic areas of colorectal tumours. Eur J Surg Oncol 29 (6), 491-496.
15. Löhr M, Maisonneuve P, and Lowenfels AB (2000). K-ras mutations and benign pancreatic disease. Int J Pancreatol 27, 93-103.
16. Heatley MK (2000). Systematic review and meta-analysis in anatomic pathology. Histopathology 36 (6), 481-487 (June).
17. Lüttges J, Galehdari H, Brocker V, Schwarte-Waldhoff I, Henne-Bruns D, Klöppel G, Schmiegel W, and Hahn SA (2001). Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 158 (5), 1677-1683 (May).
18. Rosty C, Geradts J, Sato N, Wilentz RE, Roberts H, Sohn T, Cameron JL, Yeo CJ, Hruban RH, and Goggins M (2003). p16 inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 27 (12), 1495-1501.
19. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, and Hruban RH (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60 (7), 2002-2006 (April 1).
20. Oxman AD (1994). Checklists for review articles. BMJ 309 (6955), 648-651 (September 10).
21. Lüttges J and Klöppel G (2001). Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: precursor lesions and new tumor entities. Dig Dis 18, 15-23.
22. Wilson EB (1927). Probable inference, the law of succession, and statistical inference. J Am Stat Ass 22, 209-212.
23. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, and Kato Y (1993). Frequent c-ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53, 953-956.
24. Moore PS, Beghelli S, Zamboni G, and Scarpa A (2003). Genetic abnormalities in pancreatic cancer. Mol Cancer 2 (1), 7.
25. Longnecker DS and Terhune PG (1998). What is the true rate of k-ras mutation in carcinoma of the pancreas? Pancreas 17, 323-324.
26. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, Yoshida H, Machinami R, Kishi K, and Omata M (1996). Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110, 227-231.
27. Berger DH, Chang H, Wood M, Huang L, Heath CW, Lehman T, and Ruggeri BA (1999). Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking. Cancer 85, 326-332.
28. Ellis I, Lerch MM, and Whitcomb DC (2001). Genetic testing for hereditary pancreatitis: guidelines for indications, counselling, consent and privacy issues. Pancreatology 1 (5), 405-415.
29. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, and Shirai T (2000). Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 156 (6), 2123-2133.
30. van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, Offerhaus GJ, Hicks JL, Wilentz RE, Goggins MG, De Marzo AM, Hruban RH, et al. (2002). Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161 (5), 1541-1547.
31. Goggins M, Hruban RH, and Kern SE (2000). BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156 (5), 1767-1771.
32. Maass N, Hojo T, Ueding M, Luttges J, Klöppel G, Jonat W, and Nagasaki K (2001). Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 7 (4), 812-817.
33. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Klöppel G, Kalthoff H, Ungefroren H, Lohr M, et al. (2001). Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439 (6), 798-802.
34. Real FX (2003). A catastrophic hypothesis for pancreas cancer progression. Gastroenterology 124 (7), 1958-1964.
35. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, Wilentz RE, Argani P, Sohn TA, Yeo CJ, Cameron JL, Kern SE, and Hruban RH (2000). Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 157 (3), 755-761 (September).
36. Lüttges J, Neumann S, Jesnowski R, Borries V, Löhr M, and Klöppel G (2003). Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. Pancreas 27 (6), e57-e62.
37. Heinmoller E, Dietmaier W, Zirngibl H, Heinmoller P, Scaringe W, Jauch KW, Hofstadter F, and Ruschoff J (2000). Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 157 (1), 83-92 (July).
38. Hruban RH, Wilentz RE, and Kern SE (2000). Genetic progression in the pancreatic ducts. Am J Pathol 156 (6), 1821-1825 (June).
39. Löhr M, Müller P, Schmidt C, Zauner I, Trautmann B, Thévenod F, Capellá G, Ibrahim S, Farré A, Liebe S, and Jesnowski R (2001). Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras. Virchows Arch 438, 581-590.
40. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA (1999). Creation of human tumor cells with defined genetic elements. Nature 400, 464-468.
41. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (6), 437-450.
42. Klein WM, Hruban RH, Klein-Szanto AJ, and Wilentz RE (2002). Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 15 (4), 441-447.
43. Löhr M, Müller P, Mora J, Brinkmann B, Ostwald C, Plath F, Farré A, Lluis F, Adam U, Hopt UT, Barten M, Nizze H, et al. (2001). p53 and ras mutations in pancreatic juice samples of patients with chronic pancreatitis. Gastrointest Endosc 53, 734-743.
44. Group PIs Porta M, Malais N, Guarner L, Carrato A, Rifá J, Salas A, Corominas JM, Andreu M, and Real FX (1999). Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health 53, 702-709.
45. Andea A, Sarkar F, and Adsay VN (2003). Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 16 (10), 996-1006.
46. Salaspuro V and Salaspuro M (2004). Synergistic effect of alcohol drinking and smoking on in vivo acetaldehyde concentration in saliva. Int J Cancer 111, 480-483 (DOI 10.1002/ijc.20293).
47. Kadlubar FF, Anderson KE, Haussermann S, Lang NP, Barone GW, Thompson PA, MacLeod SL, Chou MW, Mikhailova M, Plastaras J, Marnett LJ, Nair J, et al. (1998). Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res 405 (2), 125-133.
48. VanderVeen LA, Hashim MF, Shyr Y, and Marnett LJ (2003). Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde. Proc Natl Acad Sci USA 100 (24), 14247-14252.
49. Casini A, Galli A, Pignalosa P, Frulloni L, Grappone C, Milani S, Pederzoli P, Cavallini G, and Surrenti C (2000). Collagen type I synthesized by pancreatic periacinar stellate cells (PSC) co-localizes with lipid peroxidation-derived aldehydes in chronic alcoholic pancreatitis. J Pathol 192 (1), 81-89.
50. Alguacil J, Porta M, Kauppinen T, Malais N, Kogevinas M, and Carrato A (2003). Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. Int J Cancer 107 (4), 635-641.
51. Lees NP, Harrison KL, Hall CN, Margison GP, and Povey AC (2004). Reduced MGMT activity in human colorectal adenomas is associated with K-ras GC→AT transition mutations in a population exposed to methylating agents. Carcinogenesis 25 (7), 1243-1247.
52. Kaina B and Christmann M (2002). DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40 (8), 354-367.
53. Klöppel G and Lüttges J (2004). The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians. Curr Gastroenterol Rep 6 (2), 111-118.
54. Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T, and Kanematsu T (1993). Detection of point mutations in the kirsten-ras oncogene provides evidence of the multicentricity of pancreatic carcinoma. Ann Surg 217, 138-143.
55. Tabata T, Fujimori T, Maeda S, Yamamoto M, and Saitoh Y (1993). The role of ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol 14, 237-244.
56. Sugio K, Molberg K, Albores-Saavedra J, Virmani AK, Kishimoto Y, and Gazdar AF (1997). K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers. Int J Pancreatol 21, 205-217.
57. Z'graggen K, Rivera JA, Compton CC, Pins M, Werner J, Fernândez-del Castillo C, Rattner DW, Lewandrowski KB, Rustgi AK, and Warshaw AL (1997). Prevalence of activating k-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 226, 491-500.
58. Matsubayashi H, Watanabe H, Yamaguchi T, Ajioka Y, Nishikura K, Iwafuchi M, Yamano M, Kijima H, and Saito T (1999). Multiple K-ras mutations in hyperplasia and carcinoma in cases of human pancreatic carcinoma. Jpn J Cancer Res 90 (8), 841-848 (August).
59. Terhune PG, Phifer DM, Tosteson TD, and Longnecker DS (1998). K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomark Prev 7, 515-521.
60. Mulligan NJ, Yang S, Andry C, Klein M, and O'Brien MJ (1999). The role of p21ras in pancreatic neoplasia and chronic pancreatitis. Hum Pathol 30 (6), 602-610.
61. Song MM, Nio Y, Sato Y, Tamura K, and Furuse K (1996). Clinicopathological significance of ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int J Pancreatol 20 (2), 85-93.
62. Rivera JA, Rail CJN, Graeme-Cook F, Fernândez-del Castillo C, Shu P, Lakey N, Tepper R, Rattner DW, Warshaw AL, and Rustgi AK (1997). Analysis of k-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery 121 (1), 42-49.
63. Agoff SN, Crispin DA, Bronner MP, Dail DH, Hawes SE, and Haggitt RC (2001). Neoplasms of the ampulla of water with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol 14 (3), 139-146.